For decades, Depo-Provera (the “birth control shot”) has been a go-to for millions of women seeking convenient, long-term contraception. However, recent landmark studies and a major FDA update have brought a serious potential side effect into the spotlight: intracranial meningioma.
If you or a loved one have used Depo-Provera, here is a breakdown of the recent findings, the actual risks, and what the medical community is doing about it.
The Core Discovery: What the Research Says
While the link between high-dose progestogens and brain tumors has been studied before, 2024 and 2025 brought new, specific data regarding medroxyprogesterone acetate (the active ingredient in Depo-Provera).
- The 2024 BMJ Study: A massive French study published in The BMJ analyzed over 18,000 women. It found that those who used Depo-Provera for more than one year had a 5.55-fold increased risk of developing a meningioma that required surgery.
- The 2025 JAMA Neurology Study: A follow-up U.S.-based study confirmed these concerns. Researchers found a 2.43-fold increased risk specifically in long-term users (typically defined as 4+ years) or those who began the injections after age 31.
- The Biology: Meningiomas are tumors that grow from the membranes surrounding the brain and spinal cord. Because these tumors often have progesterone receptors, the synthetic hormones in Depo-Provera may act as “fuel,” stimulating their growth.
Understanding the Risk: “Relative” vs. “Absolute”
It is important to put these numbers in perspective. While a “5-fold increase” sounds terrifying, meningiomas are rare in the general population.
| Metric | Context |
| Relative Risk | Users are roughly 2 to 5 times more likely to develop the tumor than non-users. |
| Absolute Risk | One study estimated the “Number Needed to Harm” is 1,152. This means for every 1,152 women on Depo-Provera, one additional case of meningioma might occur. |
| Tumor Type | Most meningiomas are benign (non-cancerous), but they can cause serious issues by pressing on brain tissue. |
Major Update: The FDA Steps In
In December 2025, the FDA officially updated the labeling for Depo-Provera to include a warning for meningioma. The new guidelines advise:
- Discontinuation: If a patient is diagnosed with a meningioma, Depo-Provera must be stopped immediately.
- Monitoring: Doctors are now urged to monitor patients for neurological symptoms during use.
Symptoms to Watch For
Because meningiomas grow slowly, symptoms can be subtle at first. If you have a history of long-term Depo-Provera use, consult a doctor if you experience:
- Persistent headaches (often worse in the morning).
- Vision changes (blurred or double vision).
- Seizures or sudden fainting spells.
- Hearing loss or ringing in the ears.
- Memory loss or significant mood shifts.
The Bottom Line
If you are currently on Depo-Provera, do not panic or stop your medication abruptly. The risk remains low for short-term users. However, if you have been on the shot for several years, it is worth having an open conversation with your healthcare provider about switching to a non-hormonal or different hormonal alternative (like an IUD, which the studies showed did not carry this same risk).
Note: As of April 2026, thousands of legal claims have been filed regarding the failure to warn patients of these risks. If you were diagnosed with a meningioma after long-term use, you may want to consult with a medical professional to document your history. Jason Ochs at Ochs Law is actively reviewing these cases. Please text us confidentially to set up a free consult.
